Aurinia Pharmaceuticals to Acquire Kezar Life Sciences for $51.3M Cash Plus CVRs for Autoimmune Asset

summarizeSummary

Aurinia Pharmaceuticals announced the definitive agreement to acquire Kezar Life Sciences for $6.955 per share in cash plus CVRs, adding a clinical-stage autoimmune asset, zetomipzomib, to its pipeline.

check_boxKey Events

• Acquisition of Kezar Life Sciences

  Aurinia Pharmaceuticals Inc. will acquire Kezar Life Sciences, Inc. for $6.955 per share in cash, totaling approximately $51.3 million, plus one non-transferable Contingent Value Right (CVR) per share.

• Strategic Asset Addition

  The acquisition includes Kezar's lead product candidate, zetomipzomib, a clinical-stage immunoproteasome inhibitor with positive Phase 2 data in autoimmune hepatitis, lupus nephritis, and systemic lupus erythematosus.

• Contingent Value Rights (CVRs)

  CVRs provide potential future payments tied to the clinical development and commercialization of zetomipzomib (up to $88 million in milestones plus 3% royalties on net sales), proceeds from existing collaborations, and Kezar's closing net cash in excess of $50 million.

• Shareholder Support and Timeline

  Tang Capital Partners, LP, a 9.0% owner of Kezar, has agreed to tender its shares. The tender offer is expected to commence by April 13, 2026, with the transaction closing in the second quarter of 2026.

auto_awesomeAnalysis

Aurinia Pharmaceuticals is acquiring Kezar Life Sciences, a strategic move to expand its pipeline in autoimmune diseases. The deal, valued at $6.955 per share in cash plus contingent value rights (CVRs), brings Kezar's lead asset, zetomipzomib, a promising immunoproteasome inhibitor with positive Phase 2 data in autoimmune hepatitis. The CVR structure, which includes up to $88 million in potential milestones and royalties, aligns future payments with the successful development and commercialization of zetomipzomib, mitigating upfront risk while providing significant upside potential. This acquisition strengthens Aurinia's position in the autoimmune market, building on its existing LUPKYNIS franchise.